{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:51:42Z","timestamp":1792651902244,"version":"4.5.0"},"reference-count":30,"publisher":"American Association for Cancer Research (AACR)","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Tuspetinib (TUS) is a well-tolerated, once daily, oral kinase inhibitor in clinical development for treatment of acute myeloid leukemia (AML). Nonclinical studies show that TUS targets key prosurvival kinases with IC50 values in the low nmol\/L range, including SYK, wild-type (WT) and mutant forms of FLT3, mutant but not WT forms of KIT, RSK2, and TAK1\u2013TAB1 kinases, and indirectly suppresses expression of MCL1. Oral TUS markedly extended survival in subcutaneously and orthotopically inoculated xenograft models of FLT3-mutant human AML, was well tolerated, and delivered enhanced activity when combined with venetoclax (VEN) or 5-azacytidine. In vitro, TUS demonstrated potent killing of AML lines [concentration needed to reduce the growth of treated cells to half that of untreated cells (GI50) = 1.3\u20135.2 nmol\/L] and Ba\/F3 cells expressing WT (GI50 = 9.1 nmol\/L) or various mutant forms of FLT3 (GI50 = 2.5\u201356 nmol\/L). In AML lines, the multikinase targeting capacity of TUS suppressed phosphorylation of SYK, FLT3, STAT5, MEK, ERK, AKT, mTOR, 4E-BP1, and S6K kinases. Cells selected for stable acquired resistance to TUS exhibited increased BAX and hypersensitivity to VEN (1900 fold), navitoclax, and MCL1 inhibitors. MV-4-11 FLT3-ITD clones expressing NRASG12D revealed that high-level expression of NRASG12D generated modest resistance to TUS and greater resistance to VEN, yet the TUS\/VEN combination exhibited synergy in the NRASG12D AML model. Favorable preclinical safety and pharmacology properties, the efficacy of the TUS\/VEN combination in a murine model, and the synthetic lethal vulnerability to VEN that accompanies TUS resistance provide the basis for exploration of the TUS\/VEN combination in patients with relapsed or refractory AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This article reports preclinical development of TUS, an oral kinase inhibitor currently in clinical development for treatment of AML. The article covers the studies of TUS activities on cellular targets and the nonclinical studies that supported the advancement of TUS to a phase I\/II trial of TUS\/VEN in refractory AML and a phase I\/II trial of TUS\/VEN\/5-azacytidine in newly diagnosed patients with AML (NCT03850574).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0258","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T09:50:43Z","timestamp":1733997043000},"page":"74-83","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-7636","authenticated-orcid":false,"given":"Himangshu","family":"Sonowal","sequence":"first","affiliation":[{"name":"1Department of Medicine and the Moores Cancer Center, University of California, San Diego, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-9474","authenticated-orcid":false,"given":"William G.","family":"Rice","sequence":"additional","affiliation":[{"name":"2Aptose Biosciences, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5603-4598","authenticated-orcid":false,"given":"Raphael","family":"Bejar","sequence":"additional","affiliation":[{"name":"2Aptose Biosciences, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7865-2493","authenticated-orcid":false,"given":"Joo-Yun","family":"Byun","sequence":"additional","affiliation":[{"name":"3Hanmi R&D Center, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7391-8779","authenticated-orcid":false,"given":"Seung Hyun","family":"Jung","sequence":"additional","affiliation":[{"name":"3Hanmi R&D Center, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2120-9714","authenticated-orcid":false,"given":"Ranjeet","family":"Sinha","sequence":"additional","affiliation":[{"name":"2Aptose Biosciences, Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-8226","authenticated-orcid":false,"given":"Stephen B.","family":"Howell","sequence":"additional","affiliation":[{"name":"1Department of Medicine and the Moores Cancer Center, University of California, San Diego, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"2025051308480045100_bib1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"2025051308480045100_bib2","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2025051308480045100_bib3","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med"},{"key":"2025051308480045100_bib4","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","article-title":"FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"76","author":"Traer","year":"2016","journal-title":"Cancer Res"},{"key":"2025051308480045100_bib5","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"key":"2025051308480045100_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41467-018-08263-x","article-title":"Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"key":"2025051308480045100_bib7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/blood-2018-03-838946","article-title":"CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells","volume":"133","author":"Edwards","year":"2019","journal-title":"Blood"},{"key":"2025051308480045100_bib8","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"key":"2025051308480045100_bib9","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv"},{"key":"2025051308480045100_bib10","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-020-01077-1","article-title":"Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo","volume":"35","author":"Rummelt","year":"2021","journal-title":"Leukemia"},{"key":"2025051308480045100_bib11","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1182\/bloodadvances.2020002127","article-title":"Cell interactions in the bone marrow microenvironment affecting myeloid malignancies","volume":"4","author":"Kokkaliaris","year":"2020","journal-title":"Blood Adv"},{"key":"2025051308480045100_bib12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/ijc.33908","article-title":"Microenvironment and drug resistance in acute myeloid leukemia: do we know enough?","volume":"150","author":"Ganesan","year":"2022","journal-title":"Int J Cancer"},{"key":"2025051308480045100_bib13","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1182\/blood-2012-09-457887","article-title":"\u03b22 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk\/STAT signaling axis","volume":"121","author":"Oellerich","year":"2013","journal-title":"Blood"},{"key":"2025051308480045100_bib14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.gendis.2023.01.008","article-title":"Signaling pathways governing the behaviors of leukemia stem cells","volume":"11","author":"Azizidoost","year":"2023","journal-title":"Genes Dis"},{"key":"2025051308480045100_bib15","doi-asserted-by":"crossref","first-page":"896426","DOI":"10.3389\/fonc.2022.896426","article-title":"Drug resistance mechanisms of acute myeloid leukemia stem cells","volume":"12","author":"Niu","year":"2022","journal-title":"Front Oncol"},{"key":"2025051308480045100_bib16","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025051308480045100_bib17","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh Mali","year":"2021","journal-title":"Haematologica"},{"key":"2025051308480045100_bib18","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"key":"2025051308480045100_bib19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"key":"2025051308480045100_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors","volume":"2","author":"Alotaibi","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2025051308480045100_bib21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12185-023-03681-0","article-title":"FLT3 targeting in the modern era: from clonal selection to combination therapies","volume":"120","author":"Kennedy","year":"2024","journal-title":"Int J Hematol"},{"key":"2025051308480045100_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","article-title":"Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia","volume":"13","author":"Gebru","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2025051308480045100_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ccr.2014.01.022","article-title":"SYK is a critical regulator of FLT3 in acute myeloid leukemia","volume":"25","author":"Puissant","year":"2014","journal-title":"Cancer Cell"},{"key":"2025051308480045100_bib24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s41419-020-03156-8","article-title":"SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism","volume":"11","author":"Polak","year":"2020","journal-title":"Cell Death Dis"},{"key":"2025051308480045100_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MOH.0000000000000698","article-title":"Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes","volume":"29","author":"Shimony","year":"2022","journal-title":"Curr Opin Hematol"},{"key":"2025051308480045100_bib26","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s42003-021-02564-6","article-title":"The multiple mechanisms of MCL1 in the regulation of cell fate","volume":"4","author":"Widden","year":"2021","journal-title":"Commun Biol"},{"key":"2025051308480045100_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41420-023-01317-0","article-title":"The GSK3\u03b2\/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors","volume":"9","author":"Qiu","year":"2023","journal-title":"Cell Death Discov"},{"key":"2025051308480045100_bib28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1158\/2767-9764.CRC-23-0379","article-title":"Pim kinase inhibitors increase gilteritinib cytotoxicity in FLT3-ITD acute myeloid leukemia through GSK-3\u03b2 activation and c-myc and mcl-1 proteasomal degradation","volume":"4","author":"Lee","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2025051308480045100_bib29","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"Suppl 1","key":"2025051308480045100_bib30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/blood-2023-182296","article-title":"Tuspetinib myeloid kinase inhibitor safety and efficacy as monotherapy and combined with venetoclax in phase 1\/2 trial of patients with relapsed or refractory (R\/R) acute myeloid leukemia (AML)","volume":"142","author":"Daver","year":"2023","journal-title":"Blood"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0258\/3525163\/crc-24-0258.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/1\/74\/3532666\/crc-24-0258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/1\/74\/3532666\/crc-24-0258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T08:48:14Z","timestamp":1747126094000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/1\/74\/751014\/Preclinical-Development-of-Tuspetinib-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0258","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.28193245","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193257","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193227","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193239","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050330","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050312","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28893291","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050324","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193251","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050336","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193263","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28893285","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193221","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28893273","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193233","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28893279","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28893267","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050309","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193224","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193236","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193248","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193218","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050321","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28893282","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050333","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193260","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28893270","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28893276","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193230","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28893264","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050315","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193242","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050327","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28193254","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050318","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28893288","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7623112","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}